Support LinksChrome Firefox Safari Edge View Versions © 2026 Advarra, Inc.

To search for a clinical trial (protocol), use any or all of the search fields: Select from drop down lists or type search criteria in any of the text fields. Browse by Physician or Drug, use the …

SIP Version 14.0.0.010 Copyright © 2001-2020 Forte Research Systems, Inc. all rights reserved.

Objectives Primary Objective To compare overall survival in participants with newly diagnosed metastatic renal cell carcinoma who are randomized to receive immune checkpoint inhibitor …

Inclusion Criteria PATIENT SELECTION, ELIGIBILITY, AND INELIGIBILTY CRITERIA: Note: Per NCI guidelines, exceptions to inclusion and exclusion criteria are not permitted. For questions …

Objectives Stage 1, Safety Run-In Primary Objective: Evaluate the safety and tolerability of tazemetostat in combination with lenalidomide + rituximab (R2) in subjects with …

Inclusion Criteria Age 18 years or older;At least one measurable lesion according to RECIST v1.1 OR evaluable disease for a limited number of patients (up to 10) in Group H;Performance …

To evaluate the safety and tolerability of BGB-11417 in combination with dexamethasone and dexamethasone plus carfilzomib in patients with relapsed/refractory (R/R) multiple myeloma …

Objectives Primary Objective To evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and …

To evaluate the anti-tumor activities (RECIST-defined response rate, median PFS) and safety profiles of ipilimumab + nivolumab and dabrafenib-trametinib in a Cooperative Group trial of …